A Phase 3 interventional study of Empagliflozin and Placebo in Heart Failure, sponsored by Boehringer Ingelheim. Completed at 520 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-18.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing empagliflozin in Heart Failure — 16 open to participants now, 22 under way, 7 of them phase 3. empagliflozin · Heart Failure.
Among the 51 studies testing empagliflozin in Heart Failure, this one is the 3rd largest by enrollment, is one of 9 that started in 2017, is one of 14 in phase 3, and was the 3rd registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →16 of the 51 studies testing empagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Christian Schulze · Sites in Germany
Ages 18+
Ain Shams University · Sites in Egypt
Ages 1 mo–18 yrs
University of Alberta · Sites in Canada
Ages 18+
Fazaia Ruth Pfau Medical College · Sites in Pakistan
Ages 40–70
By country, each count listing its studies:
empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 15 · Phase 4 16
First in 2017; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,730 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 90 across the 51 interventional studies. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 51 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
14 studies in Heart Failure by Boehringer Ingelheim: 4 open now, 4 under way, 2 of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 14 studies in Heart Failure by Boehringer Ingelheim, this one is one of 2 that started in 2017, is one of 8 in phase 3, and was the 2nd registered.
Boehringer Ingelheim’s Heart Failure studies by the year they started, since 2009.
8 of the studies testing empagliflozin in Heart Failure that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05392764Phase 3Juntendo UniversityEarly Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure | 2026-12-31 |
| NCT05879276Phase 3Central Hospital, Nancy, FranceEffect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. | 2027-03-16 |
| NCT07038356Phase 3Christian SchulzeEffects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure | 2027-04-30 |
| NCT07692256Ain Shams Universitythe Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients | 2026-12-01 |
| NCT06260059Anita SarafEfficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 51 studies testing empagliflozin in Heart Failure, from their registry updates:
Among Boehringer Ingelheim’s 14 in Heart Failure:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with chronic HF (Chronic Heart Failure) (New York Heart Association Classification) class II-IV and reduced EF () (LVEF (Left Ventricular Ejection Fraction) \<=40%) and elevated NT-proBNP (N-terminal of the prohormone brain natriuretic peptide)
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Empagliflozin
Drug: Placebo
once daily
Also known as: JARDIANCE, JARDIANZ, GIBTULIO
once daily
Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF)
Time to the first event of adjudicated cardiovascular (CV) death or adjudicated hospitalisation for heart failure (HHF). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.
Time frame: From randomisation until completion of the planned treatment period, up to 1040 days.
Occurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent)
Reported is the total number of HHF events (first and recurrent) which occurred. All data up to the end of the planned treatment period (including the data after the end of treatment for patients not completing the treatment period as planned) from all randomised patients was used.
Time frame: From randomisation until completion of the planned treatment phase, up to 1040 days.
eGFR (CKD-EPI) cr Slope of Change From Baseline
Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) \[mL/min/1.73m2\] slope of change from baseline. Available on-treatment change-from-baseline data were to be used. Patients without on-treatment data after randomisation were not to be included in this analysis. Slope represents the long term effect on eGFR. Timepoints after baseline were included in calculation of slope of change from baseline. Descriptive statistic (mean(standard error)) is reported.
Time frame: Assessed at baseline, week 4, 12, 32, 52, 76, 100, 124, 148 and at end of treatment (EOT), up to 1040 days.
Time to First Event in Composite Renal Endpoint: Chronic Dialysis, Renal Transplant or Sustained Reduction of eGFR(CKD-EPI)cr
Time to the first event in the composite renal endpoint: chronic dialysis (with a frequency of twice per week or more for at least 90 days), renal transplant, or sustained reduction in Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.
Time frame: From randomisation until completion of the planned treatment period, up to 1040 days.
Time to First Adjudicated Hospitalisation for Heart Failure (HHF)
Time to first adjudicated Hospitalisation for Heart Failure (HHF). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.
Time frame: From randomisation until completion of the planned treatment period, up to 1040 days.
Time to Adjudicated Cardiovascular (CV) Death
Time to adjudicated CV (Cardiovascular) death. The incidence rate (patients with events per 100 person years at risk) is reported. The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.
Time frame: From randomisation until completion of the planned treatment period, up to 1040 days.
Time to All-cause Mortality
Time to all-cause mortality. The incidence rate (patients with events per 100 person years at risk) is reported. The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.
Time frame: From randomisation until completion of the planned treatment period, up to 1040 days.
Time to Onset of Diabetes Mellitus (DM)
Time to onset of DM (Glycated haemoglobin (HbA1c) ≥6.5% or as diagnosed by the investigator) in patients with pre-DM (no history of DM and no HbA1c ≥6.5% before treatment, and a pre-treatment HbA1c value of 5.7 to \<6.5%). The incidence rate (patients with events per 100 person years at risk) is reported. The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.
Time frame: From randomisation until completion of the planned treatment period, up to 1040 days.
Change From Baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score at Week 52
Change from baseline in KCCQ (Kansas City cardiomyopathy questionnaire) clinical summary score at Week 52. The KCCQ is a 23-item self-administered questionnaire designed to evaluate physical limitations, symptoms (frequency, severity, and changes over time), social limitations, selfefficacy, and quality of life in patients with Heart Failure. The KCCQ-clinical summary score comprises the following domains: Symptom frequency, symptom burden and physical limitation. The score is calculated by summing domain responses and then transforming scores to a 0-100 unit scale with higher scores indicating better health status. For patients who died, a worst score (score of 0) is imputed at all subsequent scheduled visits after the date of death. Standard error is adjusted standard error. Change from baseline in KCCQ-score at week 52 was modeled using a MMRM with visit (week 12, 32 and 52) as repeated measures, adjusted mean (standard error) at week 52 is reported.
Time frame: Assessed at baseline, week 12, week 32 and week 52.
Number of All-cause Hospitalizations (First and Recurrent)
Number of all-cause hospitalizations (first and recurrent).
Time frame: From randomisation until completion of the planned treatment phase, up to 1040 days.
A randomised, double-blind trial to demonstrate superiority of empagliflozin versus placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF).
| Milestone | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Started | 1867 | 1863 |
| Treated | 1863 | 1863 |
| Completed | 1352 | 1381 |
| Not completed | 515 | 482 |
| Withdrew: Withdrawal by subject | 124 | 92 |
| Withdrew: Lost to follow-up | 11 | 17 |
| Withdrew: Protocol violation | 6 | 5 |
| Withdrew: Not treated | 4 | 0 |
| Withdrew: Adverse event | 343 | 337 |
| Withdrew: Reason unknown | 0 | 1 |
| Withdrew: Personal reasons | 1 | 1 |
| Withdrew: Unblinded medication | 1 | 0 |
| Withdrew: Patient received empagliflozin for diabetes | 1 | 1 |
| Withdrew: Principle investigator decision | 2 | 0 |
| Withdrew: Other medical condition (no adverse event) | 2 | 4 |
| Withdrew: Patient moved away/being abroad | 4 | 3 |
| Withdrew: Unable to continue treatment | 4 | 1 |
| Withdrew: Not attending study visit | 3 | 10 |
| Withdrew: Due to covid-19 pandemic | 1 | 4 |
| Withdrew: Patient decision to stop/interrupt medication | 8 | 6 |
| Milestone | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Started | 1867 | 1863 |
| Treated | 1863 | 1863 |
| Completed | 1847 | 1841 |
| Not completed | 20 | 22 |
| Withdrew: Lost to follow-up to primary endpoint | 9 | 9 |
| Withdrew: Limited follow-up agreed | 2 | 2 |
| Withdrew: Withdrawal by subject | 9 | 11 |
Time to the first event of adjudicated cardiovascular (CV) death or adjudicated hospitalisation for heart failure (HHF). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.
| Patients with events/ 100 pt-yrs at risk | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) | 21.00 (19.13 to 22.96) | 15.77 (14.19 to 17.44) |
Reported is the total number of HHF events (first and recurrent) which occurred. All data up to the end of the planned treatment period (including the data after the end of treatment for patients not completing the treatment period as planned) from all randomised patients was used.
| HHF events | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Occurrence of Adjudicated Hospitalisation for Heart Failure (HHF) (First and Recurrent) | 553 | 388 |
Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr) \[mL/min/1.73m2\] slope of change from baseline. Available on-treatment change-from-baseline data were to be used. Patients without on-treatment data after randomisation were not to be included in this analysis. Slope represents the long term effect on eGFR. Timepoints after baseline were included in calculation of slope of change from baseline. Descriptive statistic (mean(standard error)) is reported.
| Milliliter/minute/1.73 meters squared | Placebo | 10 mg Empagliflozin |
|---|---|---|
| eGFR (CKD-EPI) cr Slope of Change From Baseline | -2.278 ± 0.229 | -0.546 ± 0.227 |
Time to the first event in the composite renal endpoint: chronic dialysis (with a frequency of twice per week or more for at least 90 days), renal transplant, or sustained reduction in Glomerular filtration rate estimated by the chronic kidney disease epidemiology collaboration formula with serum creatinine measurement (eGFR (CKD-EPI)cr). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.
| Patients with events/ 100 pt-yrs at risk | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Time to First Event in Composite Renal Endpoint: Chronic Dialysis, Renal Transplant or Sustained Reduction of eGFR(CKD-EPI)cr | 3.07 (2.33 to 3.91) | 1.56 (1.06 to 2.17) |
Time to first adjudicated Hospitalisation for Heart Failure (HHF). The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.
| Patients with events/ 100 pt-yrs at risk | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Time to First Adjudicated Hospitalisation for Heart Failure (HHF) | 15.55 (13.94 to 17.24) | 10.75 (9.45 to 12.13) |
Time to adjudicated CV (Cardiovascular) death. The incidence rate (patients with events per 100 person years at risk) is reported. The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.
| Patients with events/ 100 pt-yrs at risk | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Time to Adjudicated Cardiovascular (CV) Death | 8.13 (7.05 to 9.29) | 7.55 (6.51 to 8.67) |
Time to all-cause mortality. The incidence rate (patients with events per 100 person years at risk) is reported. The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.
| Patients with events/ 100 pt-yrs at risk | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Time to All-cause Mortality | 10.71 (9.46 to 12.04) | 10.06 (8.85 to 11.34) |
Time to onset of DM (Glycated haemoglobin (HbA1c) ≥6.5% or as diagnosed by the investigator) in patients with pre-DM (no history of DM and no HbA1c ≥6.5% before treatment, and a pre-treatment HbA1c value of 5.7 to \<6.5%). The incidence rate (patients with events per 100 person years at risk) is reported. The incidence rate per 100 patient years (100 \* number of patients with event /time at risk \[years\]) is presented. With time at risk \[year\] calculated as: Sum of time at risk \[days\] over all patients in a treatment group / 365.25. Patients without a specific endpoint event were censored at the last date the patient was known to be free of the event or at the end of the planned treatment period, whichever was earlier. Unit of Measure: Patients with events per 100 patient-years (pt-yrs) at risk.
| Patients with events/ 100 pt-yrs at risk | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Time to Onset of Diabetes Mellitus (DM) | 10.62 (8.42 to 13.07) | 9.31 (7.27 to 11.60) |
Change from baseline in KCCQ (Kansas City cardiomyopathy questionnaire) clinical summary score at Week 52. The KCCQ is a 23-item self-administered questionnaire designed to evaluate physical limitations, symptoms (frequency, severity, and changes over time), social limitations, selfefficacy, and quality of life in patients with Heart Failure. The KCCQ-clinical summary score comprises the following domains: Symptom frequency, symptom burden and physical limitation. The score is calculated by summing domain responses and then transforming scores to a 0-100 unit scale with higher scores indicating better health status. For patients who died, a worst score (score of 0) is imputed at all subsequent scheduled visits after the date of death. Standard error is adjusted standard error. Change from baseline in KCCQ-score at week 52 was modeled using a MMRM with visit (week 12, 32 and 52) as repeated measures, adjusted mean (standard error) at week 52 is reported.
| Score on a scale | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Change From Baseline in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score at Week 52 | -3.36 ± 0.69 | -1.30 ± 0.69 |
Number of all-cause hospitalizations (first and recurrent).
| Hospitalizations for any cause | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Number of All-cause Hospitalizations (First and Recurrent) | 1570 | 1364 |
Collected over From first intake of study medication until end of planned treatment period + 7 days (Residual Effect Period), up to 1047 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 266/1,867 (14.2%) | 896/1,863 (48.1%) | 369/1,863 (19.8%) |
| 10 mg Empagliflozin | 249/1,863 (13.4%) | 772/1,863 (41.4%) | 328/1,863 (17.6%) |
| Event | Placebo | 10 mg Empagliflozin |
|---|---|---|
| Cardiac failureCardiac disorders | 444/1863 | 332/1863 |
| PneumoniaInfections and infestations | 62/1863 | 53/1863 |
| Ventricular tachycardiaCardiac disorders | 37/1863 | 55/1863 |
| Acute kidney injuryRenal and urinary disorders | 55/1863 | 35/1863 |
| Atrial fibrillationCardiac disorders | 44/1863 | 24/1863 |
| Cardiac failure congestiveCardiac disorders | 41/1863 | 26/1863 |
| Cardiac failure chronicCardiac disorders | 32/1863 | 18/1863 |
| Cardiac failure acuteCardiac disorders | 29/1863 | 19/1863 |
| DeathGeneral disorders | 27/1863 | 20/1863 |
| Renal impairmentRenal and urinary disorders | 27/1863 | 17/1863 |
| Event | Placebo | 10 mg Empagliflozin |
|---|---|---|
| HypotensionVascular disorders | 109/1863 | 120/1863 |
| HyperuricaemiaMetabolism and nutrition disorders | 115/1863 | 63/1863 |
| HyperkalaemiaMetabolism and nutrition disorders | 109/1863 | 99/1863 |
| NasopharyngitisInfections and infestations | 94/1863 | 89/1863 |
Randomised Set (RS): All randomised patients.
| Age, Continuous(Years) | Placebo | 10 mg Empagliflozin | Total |
|---|---|---|---|
| Mean | 66.5 ± 11.2 | 67.2 ± 10.8 | 66.8 ± 11.0 |
| Sex: Female, Male(Participants) | Placebo | 10 mg Empagliflozin | Total |
|---|---|---|---|
| Female | 456 | 437 | 893 |
| Male | 1411 | 1426 | 2837 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 10 mg Empagliflozin | Total |
|---|---|---|---|
| Hispanic or Latino | 613 | 616 | 1229 |
| Not Hispanic or Latino | 1178 | 1164 | 2342 |
| Unknown or Not Reported | 76 | 83 | 159 |
| Race (NIH/OMB)(Participants) | Placebo | 10 mg Empagliflozin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 24 | 15 | 39 |
| Asian | 335 | 337 | 672 |
| Native Hawaiian or Other Pacific Islander | 6 | 8 | 14 |
| Black or African American | 134 | 123 | 257 |
| White | 1304 | 1325 | 2629 |
| More than one race | 33 | 28 | 61 |
| Unknown or Not Reported | 31 | 27 | 58 |
Showing the first 100 of 520 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2017 to primary completion in May 2020, 37 months.
Results were first posted in May 2021, 1 year after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 37 months is close to that.
Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Empagliflozin